Brain organoids grown from Alzheimer’s patients’ own cells revealed striking differences in how individual tissues respond to an SSRI antidepressant. The findings, led by Vasiliki Machairaki at Johns Hopkins Medicine, suggest these pea-sized clusters of brain tissue could one day guide personalized Alzheimer’s care.
What the researchers did
The team reprogrammed blood cells from people with Alzheimer’s disease and from healthy controls into stem cells, then coaxed them to form hindbrain organoids that produce serotonin. The study included hundreds of organoids from multiple patients. They then treated the organoids with escitalopram oxalate, a common SSRI.
What they found
Some patient-derived organoids showed increased proteins involved in serotonin signaling and neuron communication after treatment, while others showed little or no change. Organoids from healthy individuals responded differently. The work, published in Alzheimer’s & Dementia, also identified particles released by organoids that might serve as biomarkers for diagnosing Alzheimer’s or tracking its progression.
Why it matters for your brain health
Alzheimer’s affects over 7 million Americans, and up to 90% experience neuropsychiatric symptoms like anxiety and agitation. SSRI response varies widely — these organoids could help match the right drug to each person. This approach might also accelerate drug testing without relying solely on animal models.
What you can do now
While organoid technology isn’t yet available for personal use, you can support your cognitive health with regular exercise, quality sleep, and balanced nutrition. Mental stimulation — such as playing brain games or learning new skills — may also build cognitive reserve. To understand your current cognitive strengths, try a free, evidence-based IQ test.
Source: ScienceDaily Mind & Brain
Curious about your own brain? Take our free adaptive IQ test or try 306 brain training levels.
